Management and costs of severe psoriasis: The role of new biologics

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 4, Issue 5, 2004, Pages 573-579

  Feldman, Steven R ^a   Pearce, Daniel J ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Biologic; Management; Psoriasis

Indexed keywords

ADALIMUMAB; ALEFACEPT; ANTIBIOTIC AGENT; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; ETRETIN; INFLIXIMAB; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

ANTIINFLAMMATORY ACTIVITY; BONE MARROW TOXICITY; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DEMYELINATING DISEASE; DERMATOLOGY; DISEASE SEVERITY; DRUG FATALITY; DRUG INFUSION; DRUG INFUSION REACTION; DRUG RECEPTOR BINDING; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE MANAGEMENT; HEALTH CARE SYSTEM; HUMAN; LIVER TOXICITY; LUPUS ERYTHEMATOSUS; MULTIPLE SCLEROSIS; NEPHROTOXICITY; PATIENT SELECTION; PHOTOTHERAPY; PSORIASIS; REVIEW; SIDE EFFECT; SKIN INFLAMMATION; THROMBOCYTOPENIA;

EID: 5444252749     PISSN: 14737167     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737167.4.5.573     Document Type: Review

References (26)

1. Feldman SR. Psoriasis treatment. Curr. Prob. Dermatol. 10, 1-40 (1998).
2. Pettey AA, Balkrishnan R, Rapp SR, Fleischer AB, Feldman SR. Patients with palmoplantar psoriasis have more physical disability and discomfort than patients with other forms of psoriasis: implications for clinical practice. J. Am. Acad. Dermatol. 49, 271-275 (2003).
3. Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J. Am. Acad. Dermatol. 41, 401-407 (1999).
4. Rapp SR, Exum ML, Reboussin DM, Feldman SR, Fleischer A, Clark A. The physical, psychological and social impact of psoriasis. J. Health Psychol. 2, 525-537 (1997).
5. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch. Dermatol. 137, 280-284 (2001).
6. Liem WH, McCullough JL, Weinstein GD. Effectiveness of topical therapy for psoriasis: results of a national survey. Cutis 55, 306-310 (1995).
7. Christophers E. Psoriasis-epidemiology and clinical spectrum. Clin. Exp. Dermatol. 26, 314-320 (2001).
8. Mehlis SL, Gordon KB. The immunology of psoriasis and biologic immunotherapy. J. Am. Acad. Dermatol. 49, S44-S50 (2003).
9. Sander HM, Morris LF, Phillips CM, Harrison PE, Menter A. The annual cost of psoriasis. J. Am. Acad. Dermatol. 28, 422-425 (1993).
10. Feldman SR, Fleischer AB Jr, Reboussin DM et al. The economic impact of psoriasis increases with psoriasis severity. J. Am. Acad. Dermato.l 37, 564-569 (1997).
11. Housman TS, Rohrback JM, Fleischer AB Jr, Feldman SR. Phototherapy utilization for psoriasis is declining in the United States. J. Am. Acad. Dermatol. 46, 557-559 (2003).
12. Lowe NJ, Prystowsky JH, Bourget T et al. Acitretin plus UVB therapy for psoriasis. Comparisons with placebo plus UVB and acitretin alone. J. Am. Acad. Dermatol. 24, 591-594 (1991).
13. Heydendael VM, Spuls PI, Opmeer BC et al. Methotrexate versus cyclosporin in moderate-to-severe chronic plaque psoriasis. N. Engl. J. Med. 349, 658-665 (2003).
14. Robert C, Kupper TS. Inflammatory skin diseases, T-cells, and immune surveillance. N. Engl. J. Med. 341, 1817-1828.
15. Bonifati C, Ameglio F. Cytokines in psoriasis. Int. J. Dermatol. 38, 241-251 (1999).
16. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 357, 1842-1847 (2001).
17. Gottlieb AB, matheson RT, Lowe N et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch. Dermatol. 139, 1627-1632 (2003).
18. Gottlieb AB, Masud S, Ramamurthi R et al. Pharmacodynamic and pharmacokinetic response to antitumor necrosis factor-α monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris. J. Am. Acad. Dermatol. 48, 68-75 (2003 ).
19. Schopf RE, Aust H, Knop J. Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor alpha, infliximab. J. Am. Acad. Dermatol. 46, 886-891 (2002).
20. Stern RS. Inpatient hospital care for psoriasis: a vanishing practice in the United States. J. Am. Acad. Dermatol. 49, 445-450 (2003).
21. Gladdman DD. Psoriatic arthritis. In: Oxford Textbook of Rheumatology. Maddison PJ, Isneberg DA, Glass DN (Eds). Oxford Univesity Press, Oxford, UK, 1071 (1988).
22. Leonardi CL, Powers JL, Matheson RT et al. Etanercept as monotherapy in patients with psoriasis. N. Engl. J. Med. 349, 2014-2022 (2003).
23. Krueger GG, Papp KA, Stough DB, Loven KH, Gulliver WP, Ellis CN. A randomized, double-blind, placebo-controlled Phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J. Am. Acad. Dermatol. 47, 821-833 (2002).
24. Lebwohl M, Christophers E, Langley R, Ortonne JP, Roberts J, Griffiths CE. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch. Dermatol. 139, 719-727 (2003 ).
25. Ortonne J. Clinical response to alefacept: results of a phase 3 study of intramuscular administration of alefacept in patients with chronic plaque psoriasis. J. Eur. Acad. Dermatol. Venereol. 17, 12-16 (2003).
26. Gordon KB, Papp KA, Hamilton TK et al. Efalizumab for patients with moderate-to-severe plaque psoriasis: a randomized controlled trial. JAMA 290, 3073-3080 (2003).